{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:14:17Z","timestamp":1791497657405,"version":"4.3.4"},"reference-count":89,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH Division of Intramural Research"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Crimean-Congo hemorrhagic fever virus (CCHFV) is a widely distributed hemorrhagic fever virus and the cause of hemorrhagic disease in Africa, Southern and Eastern Europe, the Middle East, India and Asia. Recent emergence of CCHFV into Spain indicates that the geographic range of this virus is expanding and the presence of its tick vector in several countries without reported disease suggest that CCHFV will continue to spread. Research into CCHFV was historically limited by a lack of suitable animal models and tools to study viral pathogenesis. However, in the past few years the toolset for studying CCHFV has expanded with small animal and non-human primate models for CCHFV being developed along with a reverse genetics system that allows for investigation of viral determinants of disease. These tools have been utilized to understand how CCHFV antagonizes host restriction factors and to develop novel vaccine candidates that may help limit the substantial morbidity and mortality in humans caused by CCHFV.<\/ns4:p>","DOI":"10.12688\/f1000research.16189.1","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T12:15:08Z","timestamp":1540815308000},"page":"1715","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":103,"title":["Recent advances in understanding Crimean\u2013Congo hemorrhagic fever virus"],"prefix":"10.12688","volume":"7","author":[{"given":"David W.","family":"Hawman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-8227","authenticated-orcid":false,"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"307-417","DOI":"10.1093\/jmedent\/15.4.307","article-title":"The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa.","volume":"15","author":"H Hoogstraal","year":"1979","journal-title":"J Med Entomol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"233-6","DOI":"10.3181\/00379727-131-33847","article-title":"Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus.","volume":"131","author":"J Casals","year":"1969","journal-title":"Proc Soc Exp Biol Med."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"159-89","DOI":"10.1016\/j.antiviral.2013.07.006","article-title":"Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity.","volume":"100","author":"D Bente","year":"2013","journal-title":"Antiviral Res."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"93-119","DOI":"10.1016\/j.antiviral.2017.05.010","article-title":"The role of ticks in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus: A review of published field and laboratory studies.","volume":"144","author":"A Gargili","year":"2017","journal-title":"Antiviral Res."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"e0004210","DOI":"10.1371\/journal.pntd.0004210","article-title":"Seroepidemiological Studies of Crimean-Congo Hemorrhagic Fever Virus in Domestic and Wild Animals.","volume":"10","author":"J Spengler","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"576-80","DOI":"10.4269\/ajtmh.1993.48.576","article-title":"Transmission of Crimean-Congo hemorrhagic fever virus in two species of Hyalomma ticks from infected adults to cofeeding immature forms.","volume":"48","author":"S Gordon","year":"1993","journal-title":"Am J Trop Med Hyg."},{"key":"ref-7","article-title":"Crimean-Congo haemorrhagic fever","year":"2017"},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"203-14","DOI":"10.1016\/S1473-3099(06)70435-2","article-title":"Crimean-Congo haemorrhagic fever.","volume":"6","author":"O Erg\u00f6n\u00fcl","year":"2006","journal-title":"Lancet Infect Dis."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"640-2","DOI":"10.3201\/eid1804.111374","article-title":"Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey.","volume":"18","author":"H Bodur","year":"2012","journal-title":"Emerg Infect Dis."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"42-6","DOI":"10.1016\/j.jcv.2015.12.006","article-title":"Crucial parameter of the outcome in Crimean Congo hemorrhagic fever: Viral load.","volume":"75","author":"I Hasanoglu","year":"2016","journal-title":"J Clin Virol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1769-72","DOI":"10.3201\/eid1311.070222","article-title":"Viral load as predictor of Crimean-Congo hemorrhagic fever outcome.","volume":"13","author":"D Duh","year":"2007","journal-title":"Emerg Infect Dis."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"551-4","DOI":"10.1111\/j.1469-0691.2006.01445.x","article-title":"Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: Severity criteria revisited.","volume":"12","author":"O Ergonul","year":"2006","journal-title":"Clin Microbiol Infect."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"S801-S806","DOI":"10.1093\/clinids\/11.Supplement_4.S801","article-title":"Antibody response in Crimean-Congo hemorrhagic fever.","volume":"11 Suppl 4","author":"A Shepherd","year":"1989","journal-title":"Rev Infect Dis."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"S794-S800","DOI":"10.1093\/clinids\/11.Supplement_4.S794","article-title":"The clinical pathology of Crimean-Congo hemorrhagic fever.","volume":"11 Suppl 4","author":"R Swanepoel","year":"1989","journal-title":"Rev Infect Dis."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"374-9","DOI":"10.1016\/j.ijid.2007.09.010","article-title":"Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality.","volume":"12","author":"M Cevik","year":"2008","journal-title":"Int J Infect Dis."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"941-4","DOI":"10.1086\/500836","article-title":"Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever.","volume":"193","author":"O Ergonul","year":"2006","journal-title":"J Infect Dis."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"272-6","DOI":"10.1016\/j.jcv.2006.04.007","article-title":"Cytokine levels in Crimean-Congo hemorrhagic fever.","volume":"36","author":"A Papa","year":"2006","journal-title":"J Clin Virol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/1471-2334-14-416","article-title":"Sequential determination of serum viral titers, virus-specific IgG antibodies, and TNF-\u03b1, IL-6, IL-10, and IFN-\u03b3 levels in patients with Crimean-Congo hemorrhagic fever.","volume":"14","author":"S Kaya","year":"2014","journal-title":"BMC Infect Dis."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"21-7","DOI":"10.1002\/jmv.24312","article-title":"Cytokines as biomarkers of Crimean-Congo hemorrhagic fever.","volume":"88","author":"A Papa","year":"2016","journal-title":"J Med Virol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"38-43","DOI":"10.1016\/j.jviromet.2018.01.013","article-title":"A one-step multiplex real-time RT-PCR for the universal detection of all currently known CCHFV genotypes.","volume":"255","author":"M Sas","year":"2018","journal-title":"J Virol Methods."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"786-93","DOI":"10.1089\/vbz.2011.0770","article-title":"Development of a real-time RT-PCR assay for the detection of Crimean-Congo hemorrhagic fever virus.","volume":"12","author":"B Atkinson","year":"2012","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"870-2","DOI":"10.1089\/vbz.2014.1577","article-title":"Development and evaluation of a real-time RT-qPCR for detection of Crimean-Congo hemorrhagic fever virus representing different genotypes.","volume":"14","author":"A J\u00e4\u00e4skel\u00e4inen","year":"2014","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1909-21","DOI":"10.1093\/infdis\/jit061","article-title":"Lethal Crimean-Congo hemorrhagic fever virus infection in interferon \u03b1\/\u03b2 receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy.","volume":"207","author":"M Zivcec","year":"2013","journal-title":"J Infect Dis."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1473-7","DOI":"10.1099\/vir.0.019034-0","article-title":"Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice.","volume":"91","author":"S Bereczky","year":"2010","journal-title":"J Gen Virol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"11089-100","DOI":"10.1128\/JVI.01383-10","article-title":"Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model.","volume":"84","author":"D Bente","year":"2010","journal-title":"J Virol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"10219-29","DOI":"10.1128\/JVI.01643-15","article-title":"RIG-I Mediates an Antiviral Response to Crimean-Congo Hemorrhagic Fever Virus.","volume":"89","author":"J Spengler","year":"2015","journal-title":"J Virol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"e2032","DOI":"10.1371\/journal.pone.0002032","article-title":"Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction.","volume":"3","author":"M Habjan","year":"2008","journal-title":"PLoS One."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1090-5","DOI":"10.1002\/jmv.24174","article-title":"Toll-like receptor 7 Gln11Leu, c.4-151A\/G, and +1817G\/T polymorphisms in Crimean Congo hemorrhagic fever.","volume":"87","author":"S Arslan","year":"2015","journal-title":"J Med Virol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"1071-8","DOI":"10.1016\/j.micinf.2010.07.012","article-title":"Toll-like receptor 8 and 9 polymorphisms in Crimean-Congo hemorrhagic fever.","volume":"12","author":"A Engin","year":"2010","journal-title":"Microbes Infect."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"19-25","DOI":"10.1002\/jmv.24924","article-title":"Effect of TLR10 (2322A\/G, 720A\/C, and 992T\/A) polymorphisms on the pathogenesis of Crimean Congo hemorrhagic fever disease.","volume":"90","author":"S K\u0131z\u0131lda\u011f","year":"2018","journal-title":"J Med Virol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"138-43","DOI":"10.3109\/00365548.2011.623313","article-title":"Relationship between NF-\u03baB1 and NF-\u03baBIA genetic polymorphisms and Crimean-Congo hemorrhagic fever.","volume":"44","author":"S Arslan","year":"2012","journal-title":"Scand J Infect Dis."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"582-92","DOI":"10.1074\/jbc.M115.667436","article-title":"The Non-structural Protein of Crimean-Congo Hemorrhagic Fever Virus Disrupts the Mitochondrial Membrane Potential and Induces Apoptosis.","volume":"291","author":"B Barnwal","year":"2016","journal-title":"J Biol Chem."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"e29712","DOI":"10.1371\/journal.pone.0029712","article-title":"Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk.","volume":"7","author":"R Rodrigues","year":"2012","journal-title":"PLoS One."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"3227-34","DOI":"10.1074\/jbc.M110.149369","article-title":"Induction of caspase activation and cleavage of the viral nucleocapsid protein in different cell types during Crimean-Congo hemorrhagic fever virus infection.","volume":"286","author":"H Karlberg","year":"2011","journal-title":"J Biol Chem."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"12294-303","DOI":"10.1128\/JVI.01627-12","article-title":"Structure of Crimean-Congo hemorrhagic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage.","volume":"86","author":"Y Wang","year":"2012","journal-title":"J Virol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"2396-407","DOI":"10.1016\/j.celrep.2017.08.040","article-title":"Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.","volume":"20","author":"F Scholte","year":"2017","journal-title":"Cell Rep."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"404-16","DOI":"10.1016\/j.chom.2007.09.014","article-title":"Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses.","volume":"2","author":"N Frias-Staheli","year":"2007","journal-title":"Cell Host Microbe."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"2222-7","DOI":"10.1073\/pnas.1013388108","article-title":"Structural basis for the removal of ubiquitin and interferon-stimulated gene 15 by a viral ovarian tumor domain-containing protease.","volume":"108","author":"T James","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"423-39","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond.","volume":"16","author":"Y Perng","year":"2018","journal-title":"Nat Rev Microbiol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"3815-27","DOI":"10.1128\/JVI.03252-12","article-title":"Diversity of ubiquitin and ISG15 specificity among nairoviruses' viral ovarian tumor domain proteases.","volume":"87","author":"G Capodagli","year":"2013","journal-title":"J Virol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"8314-27","DOI":"10.1128\/JVI.00975-16","article-title":"Biochemical and Structural Insights into the Preference of Nairoviral DeISGylases for Interferon-Stimulated Gene Product 15 Originating from Certain Species.","volume":"90","author":"M Deaton","year":"2016","journal-title":"J Virol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"e0006598","DOI":"10.1371\/journal.pntd.0006598","article-title":"Epitope-mapping of the glycoprotein from Crimean-Congo hemorrhagic fever virus using a microarray approach.","volume":"12","author":"A Fritzen","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"6152-61","DOI":"10.1128\/JVI.79.10.6152-6161.2005","article-title":"Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins.","volume":"79","author":"A Bertolotti-Ciarlet","year":"2005","journal-title":"J Virol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.","volume":"9","author":"K Buttigieg","year":"2014","journal-title":"PLoS One."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"e0156637","DOI":"10.1371\/journal.pone.0156637","article-title":"Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses.","volume":"11","author":"S Dowall","year":"2016","journal-title":"PLoS One."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"560-3","DOI":"10.1016\/j.ijid.2008.08.027","article-title":"Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever.","volume":"13","author":"E Akinci","year":"2009","journal-title":"Int J Infect Dis."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"e0006149","DOI":"10.1371\/journal.pntd.0006149","article-title":"Long-lived CD8+ T cell responses following Crimean-Congo haemorrhagic fever virus infection.","volume":"11","author":"D Goedhals","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"e1038-41","DOI":"10.1016\/j.ijid.2013.06.005","article-title":"The relationship between the human leukocyte antigen system and Crimean-Congo hemorrhagic fever in the Turkish population.","volume":"17","author":"E Ak\u0131nc\u0131","year":"2013","journal-title":"Int J Infect Dis."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1386-97","DOI":"10.1093\/infdis\/jix215","article-title":"Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection.","volume":"216","author":"J Spengler","year":"2017","journal-title":"J Infect Dis."},{"key":"ref-50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01083-18","article-title":"Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.","volume":"92","author":"M Lindquist","year":"2018","journal-title":"J Virol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"556-62","DOI":"10.1038\/s41564-018-0141-7","article-title":"A cynomolgus macaque model for Crimean-Congo haemorrhagic fever.","volume":"3","author":"E Haddock","year":"2018","journal-title":"Nat Microbiol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"137-43","DOI":"10.1007\/BF01318066","article-title":"A comparative study of the Crimean hemorrhagic fever-Congo group of viruses.","volume":"62","author":"S Smirnova","year":"1979","journal-title":"Arch Virol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever.","volume":"8","author":"L Oestereich","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"18-26","DOI":"10.1016\/j.antiviral.2018.06.013","article-title":"Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice.","volume":"157","author":"D Hawman","year":"2018","journal-title":"Antiviral Res."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"e0003579","DOI":"10.1371\/journal.pntd.0003579","article-title":"Immunization of knock-out \u03b1\/\u03b2 interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine.","volume":"9","author":"N Canakoglu","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"e0005908","DOI":"10.1371\/journal.pntd.0005908","article-title":"A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.","volume":"11","author":"A Garrison","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fcimb.2017.00213","article-title":"Crimean-Congo Hemorrhagic Fever: Tick-Host-Virus Interactions.","volume":"7","author":"A Papa","year":"2017","journal-title":"Front Cell Infect Microbiol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fcimb.2017.00281","article-title":"The Essential Role of Tick Salivary Glands and Saliva in Tick Feeding and Pathogen Transmission.","volume":"7","author":"L \u0160imo","year":"2017","journal-title":"Front Cell Infect Microbiol."},{"key":"ref-59","doi-asserted-by":"publisher","DOI":"10.3390\/v10070381","article-title":"Interactions of Human Dermal Dendritic Cells and Langerhans Cells Treated with Hyalomma Tick Saliva with Crimean-Congo Hemorrhagic Fever Virus.","volume":"10","author":"S Rodriguez","year":"2018","journal-title":"Viruses."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"35819","DOI":"10.1038\/srep35819","article-title":"Transstadial Transmission and Long-term Association of Crimean-Congo Hemorrhagic Fever Virus in Ticks Shapes Genome Plasticity.","volume":"6","author":"H Xia","year":"2016","journal-title":"Sci Rep."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"6225-9","DOI":"10.1016\/j.vaccine.2012.08.003","article-title":"Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine.","volume":"30","author":"M Mousavi-Jazi","year":"2012","journal-title":"Vaccine."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"225-9","DOI":"10.3109\/00365548.2010.540036","article-title":"The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain.","volume":"43","author":"A Papa","year":"2011","journal-title":"Scand J Infect Dis."},{"key":"ref-63","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02076-16","article-title":"Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and\/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.","volume":"91","author":"J Hinkula","year":"2017","journal-title":"J Virol."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"2031-7","DOI":"10.1128\/CVI.05352-11","article-title":"Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus.","volume":"18","author":"S Ghiasi","year":"2011","journal-title":"Clin Vaccine Immunol."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"759-64","DOI":"10.1089\/vbz.2015.1855","article-title":"Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.","volume":"15","author":"J Kortekaas","year":"2015","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"1951-62","DOI":"10.1007\/s00705-017-3315-3","article-title":"Expression and characterization of codon-optimized Crimean-Congo hemorrhagic fever virus Gn glycoprotein in insect cells.","volume":"162","author":"M Rahpeyma","year":"2017","journal-title":"Arch Virol."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"e0006628","DOI":"10.1371\/journal.pntd.0006628","article-title":"Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge.","volume":"12","author":"M Zivcec","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"519-27","DOI":"10.1080\/21645515.2015.1078045","article-title":"A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.","volume":"12","author":"S Dowall","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1471-2334-10-207","article-title":"Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis.","volume":"10","author":"K Soares-Weiser","year":"2010","journal-title":"BMC Infect Dis."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"1215-22","DOI":"10.1093\/jac\/dkr136","article-title":"Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis.","volume":"66","author":"S Ascioglu","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"CD012713","DOI":"10.1002\/14651858.CD012713.pub2","article-title":"Ribavirin for treating Crimean Congo haemorrhagic fever.","volume":"6","author":"S Johnson","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"65-8","DOI":"10.1016\/j.jcv.2009.11.007","article-title":"The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey.","volume":"47","author":"I Koksal","year":"2010","journal-title":"J Clin Virol."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"1642-8","DOI":"10.3201\/eid2409.171709","article-title":"Systematic Review and Meta-analysis of Postexposure Prophylaxis for Crimean-Congo Hemorrhagic Fever Virus among Healthcare Workers.","volume":"24","author":"O Erg\u00f6n\u00fcl","year":"2018","journal-title":"Emerg Infect Dis."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"1952-6","DOI":"10.1093\/infdis\/jiy163","article-title":"Ribavirin Had Demonstrable Effects on the Crimean-Congo Hemorrhagic Fever Virus (CCHFV) Population and Load in a Patient With CCHF Infection.","volume":"217","author":"N Espy","year":"2018","journal-title":"J Infect Dis."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"154-61","DOI":"10.1056\/NEJMoa1615162","article-title":"Autochthonous Crimean-Congo Hemorrhagic Fever in Spain.","volume":"377","author":"A Negredo","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"494-503","DOI":"10.1592\/phco.27.4.494","article-title":"Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome.","volume":"27","author":"M Muller","year":"2007","journal-title":"Pharmacotherapy."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"376-84","DOI":"10.1046\/j.1524-4733.2001.45075.x","article-title":"Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.","volume":"4","author":"E Devine","year":"2001","journal-title":"Value Health."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijid.2014.08.016","article-title":"Evidence supports ribavirin use in Crimean-Congo hemorrhagic fever.","volume":"29","author":"O Ergonul","year":"2014","journal-title":"Int J Infect Dis."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"284-6","DOI":"10.1016\/j.jinf.2009.08.006","article-title":"DEBATE (see Elaldi N et al, Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. Journal of Infection 2009; 58: 238-244): Biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever.","volume":"59","author":"O Ergonul","year":"2009","journal-title":"J Infect."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"e799-801","DOI":"10.1016\/j.ijid.2013.02.030","article-title":"Ribavirin is not effective against Crimean-Congo hemorrhagic fever: Observations from the Turkish experience.","volume":"17","author":"B Ceylan","year":"2013","journal-title":"Int J Infect Dis."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"286-9","DOI":"10.1016\/j.jinf.2009.08.017","article-title":"Response to Ergonul: Scientific Evidence Versus Personal Beliefs In Crimean-Congo Haemorrhagic Fever Treatment.","volume":"59","author":"S Ascioglu","year":"2009","journal-title":"J Infect."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"117-20","DOI":"10.1136\/medethics-2011-100107","article-title":"A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: Ethical considerations.","volume":"38","author":"B Arda","year":"2012","journal-title":"J Med Ethics."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"977-81","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705.","volume":"46","author":"Y Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"17-21","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.","volume":"105","author":"L Oestereich","year":"2014","journal-title":"Antiviral Res."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"1696-9","DOI":"10.3201\/eid2409.180233","article-title":"Use of Favipiravir to Treat Lassa Virus Infection in Macaques.","volume":"24","author":"K Rosenke","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.","volume":"5","author":"D Safronetz","year":"2015","journal-title":"Sci Rep."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"855-9","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever.","volume":"65","author":"V Raabe","year":"2017","journal-title":"Clin Infect Dis."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"91-9","DOI":"10.1016\/j.antiviral.2017.10.008","article-title":"Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus.","volume":"147","author":"S Welch","year":"2017","journal-title":"Antiviral Res."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"112-20","DOI":"10.1016\/j.antiviral.2017.08.014","article-title":"Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.","volume":"146","author":"M Zivcec","year":"2017","journal-title":"Antiviral Res."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T12:17:00Z","timestamp":1553861820000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":89,"URL":"https:\/\/doi.org\/10.12688\/f1000research.16189.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.17678.r39631","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17678.r39628","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17678.r39629","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17678.r39630","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.17678.r39628, Anna Papa, Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, 29 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1#referee-response-39628","order":0,"name":"referee-response-39628","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17678.r39631, Dennis A Bente, Department of Microbiology & Immunology, Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555-0610, USA, 29 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1#referee-response-39631","order":1,"name":"referee-response-39631","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17678.r39630, Ali Mirazimi, Department for Laboratory Medicine, Karolinska Institute and Karolinska Hospital University, Solna, Sweden, 29 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1#referee-response-39630","order":2,"name":"referee-response-39630","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17678.r39629, Eric Bergeron, Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 29 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1715\/v1#referee-response-39629","order":3,"name":"referee-response-39629","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This review was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases\/National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}